{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:48:34Z","timestamp":1791460114905,"version":"4.3.4"},"reference-count":102,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>This study evaluated the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) in idiopathic intracranial hypertension (IIH), focusing on their effects on clinical outcomes, management escalation, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors conducted a cohort study using the TriNetX Research Network, comparing IIH patients treated with GLP-1-RAs to untreated patients, employing propensity score matching. Clinical outcomes, including headaches, visual and cognitive deficits, acetazolamide use, surgery, and mortality, were assessed at 6-month and 1-year follow-up (FU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      At 6-month FU, 5750 patients in the GLP-1-RA cohort were matched to 5750 in the control group. At 1-year FU, 4968 patients in the GLP-1-RA cohort were matched to 4968 in the control group. The GLP-1-RA group demonstrated a significant reduction in BMI (p &lt; 0.001) at 6 months, with a standardized mean difference of 1.083 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , which increased to 1.635 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      at 1 year. The control group showed a smaller reduction (p = 0.006), with a standardized mean difference of 0.695 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      at 6 months and 0.758 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      at 1 year. Furthermore, GLP-1-RA users had significantly lower odds of new-onset headache (OR 0.660, 95% CI 0.543\u20130.799, p &lt; 0.001), visual deficits (OR 0.423, 95% CI 0.324\u20130.546, p &lt; 0.001), cognitive deficits (OR 0.368, 95% CI 0.246\u20130.539, p &lt; 0.001), and acetazolamide use (OR 0.295, 95% CI 0.249\u20130.348, p &lt; 0.001) at 6 months. These trends persisted at 1 year for visual deficits (OR 0.606, 95% CI 0.489\u20130.747, p &lt; 0.001), cognitive deficits (OR 0.590, 95% CI 0.432\u20130.801, p = 0.006), and acetazolamide use (OR 0.374, 95% CI 0.320\u20130.437, p &lt; 0.001). Shunt placement for GLP-1-RA users also showed significantly lower risk at 1 year (OR 0.375, 95% CI 0.171\u20130.753, p = 0.047). Mortality rates were lower in the GLP-1-RA group at both 6 months (OR 0.060, 95% CI 0.031\u20130.106, p &lt; 0.001) and 1 year (OR 0.115, 95% CI 0.070\u20130.179, p &lt; 0.001). Kaplan-Meier survival curves confirmed these findings, additionally showing cumulative significance for headache reduction (p = 0.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>GLP-1-RAs may provide clinical benefits for patients with IIH, improving outcomes and reducing the need for invasive interventions. Future randomized, prospective studies are warranted to confirm these findings and optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2025.1.jns242357","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T21:51:42Z","timestamp":1746827502000},"page":"1037-1047","source":"Crossref","is-referenced-by-count":14,"title":["Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study"],"prefix":"10.3171","volume":"143","author":[{"given":"Sean","family":"O\u2019Leary","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Camarillo-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Karas","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"},{"name":"Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visish M.","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"1","key":"b1","series-title":"The International Classification of Headache Disorders, 3rd edition. Cephalalgia","first-page":"1","article-title":"Headache Classification Committee of the International Headache Society (IHS)","volume":"38","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211."},{"key":"b2","series-title":"J Clin Neurosci","first-page":"172","article-title":"Idiopathic intracranial hypertension: pathophysiology, diagnosis and management","volume":"95","author":"Wang MTM","year":"2022","unstructured":"Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci. 2022;95:172\u2013179."},{"issue":"4","key":"b3","series-title":"J Neuroophthalmol","first-page":"258","article-title":"Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension","volume":"27","author":"Warner JEA","year":"2007","unstructured":"Warner JEA, Larson AJ, Bhosale P,  Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol. 2007;27(4):258\u2013262."},{"issue":"11","key":"b4","series-title":"Neurology","first-page":"1893","article-title":"Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension","volume":"64","author":"Tabassi A","year":"2005","unstructured":"Tabassi A, Salmasi AH, Jalali M. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension. Neurology. 2005;64(11):1893\u20131896."},{"issue":"4","key":"b5","series-title":"J Neuroophthalmol","first-page":"253","article-title":"Retinol and retinol-binding protein in cerebrospinal fluid: can vitamin A take the \"idiopathic\" out of idiopathic intracranial hypertension?","volume":"27","author":"Libien J","year":"2007","unstructured":"Libien J, Blaner WS. Retinol and retinol-binding protein in cerebrospinal fluid: can vitamin A take the \"idiopathic\" out of idiopathic intracranial hypertension?. J Neuroophthalmol. 2007;27(4):253\u2013257."},{"issue":"9","key":"b6","series-title":"Dig Dis Sci","first-page":"1847","article-title":"Adipose tissue: the new endocrine organ? A review article","volume":"54","author":"Wozniak SE","year":"2009","unstructured":"Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54(9):1847\u20131856."},{"issue":"4","key":"b7","series-title":"Am J Ophthalmol","first-page":"437","article-title":"Anemia and papilledema","volume":"135","author":"Biousse V","year":"2003","unstructured":"Biousse V, Rucker JC, Vignal C, Crassard I, Katz BJ, Newman NJ. Anemia and papilledema. Am J Ophthalmol. 2003;135(4):437\u2013446."},{"issue":"5","key":"b8","series-title":"Letter. J Intern Med","first-page":"496","article-title":"Inflammatory and haemostatic markers in idiopathic intracranial hypertension","volume":"270","author":"Hannerz J","year":"2011","unstructured":"Hannerz J, Antovic JP, Blomb\u00e4ck M, Edman G, Khademi M, Piehl F. Inflammatory and haemostatic markers in idiopathic intracranial hypertension. Letter. J Intern Med. 2011;270(5):496\u2013499."},{"issue":"4","key":"b9","series-title":"Blood Coagul Fibrinolysis","first-page":"328","article-title":"Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis","volume":"21","author":"Kesler A","year":"2010","unstructured":"Kesler A, Kliper E, Assayag EB,  Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis. Blood Coagul Fibrinolysis. 2010;21(4):328\u2013333."},{"issue":"4","key":"b10","series-title":"Horm Res Paediatr","first-page":"217","article-title":"Idiopathic intracranial hypertension and obesity","volume":"81","author":"Andrews LE","year":"2014","unstructured":"Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr. 2014;81(4):217\u2013225."},{"issue":"5","key":"b11","series-title":"Ophthalmology","first-page":"697","article-title":"Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity","volume":"124","author":"Kilgore KP","year":"2017","unstructured":"Kilgore KP, Lee MS, Leavitt JA,  Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology. 2017;124(5):697\u2013700."},{"issue":"1","key":"b12","series-title":"Int J Obes Relat Metab Disord","first-page":"54","article-title":"The relationship between obesity and idiopathic intracranial hypertension","volume":"23","author":"Rowe FJ","year":"1999","unstructured":"Rowe FJ, Sarkies NJ. The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord. 1999;23(1):54\u201359."},{"issue":"8","key":"b13","series-title":"Cochrane Database Syst Rev","first-page":"CD003434","article-title":"Interventions for idiopathic intracranial hypertension","volume":"2015","author":"Piper RJ","year":"2015","unstructured":"Piper RJ, Kalyvas AV, Young AM, Hughes MA, Jamjoom AA, Fouyas IP. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015;2015(8):CD003434."},{"issue":"3","key":"b14","series-title":"Neurology","first-page":"e208036","article-title":"Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity","volume":"102","author":"Shaia JK","year":"2024","unstructured":"Shaia JK, Sharma N, Kumar M,  Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity. Neurology. 2024;102(3):e208036."},{"issue":"12","key":"b15","series-title":"Ophthalmology","first-page":"2313","article-title":"The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)","volume":"105","author":"Johnson LN","year":"1998","unstructured":"Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105(12):2313\u20132317."},{"issue":"2","key":"b16","series-title":"J Neuroophthalmol","first-page":"197","article-title":"Obesity and weight loss in idiopathic intracranial hypertension: a narrative review","volume":"37","author":"Subramaniam S","year":"2017","unstructured":"Subramaniam S, Fletcher WA. Obesity and weight loss in idiopathic intracranial hypertension: a narrative review. J Neuroophthalmol. 2017;37(2):197\u2013205."},{"issue":"4","key":"b17","series-title":"J Neuroophthalmol","first-page":"522","article-title":"Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention","volume":"38","author":"Hornby C","year":"2018","unstructured":"Hornby C, Mollan SP, Botfield H, O'Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol. 2018;38(4):522\u2013530."},{"issue":"10","key":"b18","series-title":"Expert Opin Pharmacother","first-page":"1305","article-title":"An update on pharmacotherapeutic strategies for obesity","volume":"22","author":"Tchang BG","year":"2021","unstructured":"Tchang BG, Tarazi MS, Aras M, Shukla AP. An update on pharmacotherapeutic strategies for obesity. Expert Opin Pharmacother. 2021;22(10):1305\u20131318."},{"issue":"13","key":"b19","series-title":"Int J Mol Sci","first-page":"10449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu MS","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023;24(13):10449."},{"issue":"8","key":"b20","series-title":"Postgrad Med","first-page":"818","article-title":"User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818\u2013826."},{"key":"b21","series-title":"Obes Med","first-page":"100456","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","author":"Vosoughi K","year":"2022","unstructured":"Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis. Obes Med. 2022;35:100456."},{"issue":"6","key":"b22","series-title":"Adv Ther","first-page":"2452","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle M","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M, Jane\u017e A. Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther. 2022;39(6):2452\u20132467."},{"issue":"6","key":"b23","series-title":"Curr Pain Headache Rep","first-page":"453","article-title":"Idiopathic intracranial hypertension after abrupt cessation of medication: a case report of abrupt glucagon-like peptide-1 (GLP-1) receptor agonist cessation and review of the literature","volume":"28","author":"Heckel B","year":"2024","unstructured":"Heckel B. Idiopathic intracranial hypertension after abrupt cessation of medication: a case report of abrupt glucagon-like peptide-1 (GLP-1) receptor agonist cessation and review of the literature. Curr Pain Headache Rep. 2024;28(6):453\u2013456."},{"issue":"1","key":"b24","series-title":"J Headache Pain","first-page":"89","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"Krajnc N","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S,  Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023;24(1):89."},{"issue":"5","key":"b25","series-title":"Brain","first-page":"1821","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell JL","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK,  The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821\u20131830."},{"issue":"1","key":"b26","series-title":"J Neuroophthalmol","first-page":"6","article-title":"Predictive value of international classification of diseases codes for idiopathic intracranial hypertension in a university health system","volume":"42","author":"Khushzad F","year":"2022","unstructured":"Khushzad F, Kumar R, Muminovic I, Moss HE. Predictive value of international classification of diseases codes for idiopathic intracranial hypertension in a university health system. J Neuroophthalmol. 2022;42(1):6\u201310."},{"issue":"1","key":"b27","series-title":"J Am","first-page":"133","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe JH","year":"2024","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (Wash DC). 2024;64(1):133-138."},{"issue":"11","key":"b28","series-title":"N Engl J Med","first-page":"961","article-title":"Medicare Part D coverage of antiobesity medications\u2014challenges and uncertainty ahead","volume":"388","author":"Baig K","year":"2023","unstructured":"Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare Part D coverage of antiobesity medications\u2014challenges and uncertainty ahead. N Engl J Med. 2023;388(11):961\u2013963."},{"issue":"6","key":"b29","series-title":"Br J Dermatol","first-page":"921","article-title":"Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study","volume":"190","author":"Thang CJ","year":"2024","unstructured":"Thang CJ, Garate D, O\u2019Leary S, Golovko G, Wilkerson MG, Barbieri JS. Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study. Br J Dermatol. 2024;190(6):921\u2013923."},{"issue":"1","key":"b30","series-title":"Int Ophthalmol Clin","first-page":"1","article-title":"Epidemiology and risk factors for idiopathic intracranial hypertension","volume":"54","author":"Chen J","year":"2014","unstructured":"Chen J, Wall M. Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin. 2014;54(1):1\u201311."},{"issue":"2","key":"b31","series-title":"J Am Acad Dermatol","first-page":"456","article-title":"Association between cycline antibiotic and development of pseudotumor cerebri syndrome","volume":"81","author":"Eldweik L","year":"2019","unstructured":"Eldweik L, McClelland C, Stein JD, Blachley TS, Lee MS. Association between cycline antibiotic and development of pseudotumor cerebri syndrome. J Am Acad Dermatol. 2019;81(2):456\u2013462."},{"issue":"1-2","key":"b32","series-title":"J Pain","first-page":"59","article-title":"ICD-10 codes for the study of chronic overlapping pain conditions in administrative databases","volume":"21","author":"Schrepf A","year":"2020","unstructured":"Schrepf A, Phan V, Clemens JQ, Maixner W, Hanauer D, Williams DA. ICD-10 codes for the study of chronic overlapping pain conditions in administrative databases. J Pain. 2020;21(1-2):59\u201370."},{"issue":"8","key":"b33","series-title":"JAMA Dermatol","first-page":"895","article-title":"Calcitonin gene-related peptide inhibition and development of acne and rosacea","volume":"160","author":"Thang CJ","year":"2024","unstructured":"Thang CJ, Lai J, Garate D,  Calcitonin gene-related peptide inhibition and development of acne and rosacea. JAMA Dermatol. 2024;160(8):895\u2013898."},{"issue":"8","key":"b34","series-title":"Headache","first-page":"1195","article-title":"Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial","volume":"57","author":"Friedman DI","year":"2017","unstructured":"Friedman DI, Quiros PA, Subramanian PS,  Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache. 2017;57(8):1195\u20131205."},{"issue":"7","key":"b35","series-title":"PLoS One","first-page":"e0236828","article-title":"Idiopathic intracranial hypertension in patients with anemia: a retrospective observational study","volume":"15","author":"Ma Z","year":"2020","unstructured":"Ma Z, Jiang H, Meng C, Cui S, Peng J, Wang J. Idiopathic intracranial hypertension in patients with anemia: a retrospective observational study. PLoS One. 2020;15(7):e0236828."},{"issue":"10","key":"b36","series-title":"JAMA Dermatol","first-page":"1135","article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020","volume":"159","author":"Barbieri JS","year":"2023","unstructured":"Barbieri JS. Temporal trends in the use of systemic medications for acne from 2017 to 2020. JAMA Dermatol. 2023;159(10):1135\u20131136."},{"issue":"2","key":"b37","series-title":"Am J Clin Dermatol","first-page":"163","article-title":"Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes","volume":"21","author":"Tan MG","year":"2020","unstructured":"Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. Am J Clin Dermatol. 2020;21(2):163\u2013172."},{"issue":"4","key":"b38","series-title":"Acta Med Port","first-page":"280","article-title":"Kaplan-Meier survival analysis: practical insights for clinicians","volume":"37","author":"Gomes AP","year":"2024","unstructured":"Gomes AP, Costa B, Marques R, Nunes V, Coelho C. Kaplan-Meier survival analysis: practical insights for clinicians. Acta Med Port. 2024;37(4):280\u2013285."},{"key":"b39","series-title":"Exp Diabetes Res","first-page":"672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami M","year":"2012","unstructured":"Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658."},{"issue":"7","key":"b40","series-title":"Eye (Lond)","first-page":"1374","article-title":"Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension","volume":"38","author":"Grech O","year":"2024","unstructured":"Grech O, Mitchell JL, Lyons HS,  Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension. Eye (Lond). 2024;38(7):1374-1379."},{"issue":"1","key":"b41","series-title":"Cerebrospinal Fluid Res","first-page":"10","article-title":"Multiplicity of cerebrospinal fluid functions: new challenges in health and disease","volume":"5","author":"Johanson CE","year":"2008","unstructured":"Johanson CE, Duncan JA III, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008;5(1):10."},{"issue":"404","key":"b42","series-title":"Sci Transl Med","first-page":"eaan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield HF","year":"2017","unstructured":"Botfield HF, Uldall MS, Westgate CSJ,  A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404):eaan0972."},{"issue":"1","key":"b43","series-title":"Nat Commun","first-page":"467","article-title":"Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics","volume":"11","author":"Ast J","year":"2020","unstructured":"Ast J, Arvaniti A, Fine NHF,  Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat Commun. 2020;11(1):467."},{"issue":"1","key":"b44","series-title":"J Endocrinol","first-page":"59","article-title":"A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules","volume":"201","author":"Liu H","year":"2009","unstructured":"Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59\u201366."},{"issue":"17","key":"b45","series-title":"J Neurosci","first-page":"6587","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean PL","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31(17):6587\u20136594."},{"issue":"16","key":"b46","series-title":"JAMA","first-page":"1641","article-title":"Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial","volume":"311","author":"Wall M","year":"2014","unstructured":"Wall M, McDermott MP, Kieburtz KD,  Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641\u20131651."},{"issue":"1","key":"b47","series-title":"BMJ Open Respir Res","first-page":"e000557","article-title":"Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"Schmickl CN","year":"2020","unstructured":"Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. BMJ Open Respir Res. 2020;7(1):e000557."},{"key":"b48","series-title":"Explor Drug Sci","first-page":"221","article-title":"The protective role of GLP-1 in neuro-ophthalmology","volume":"1","author":"Sheth S","year":"2023","unstructured":"Sheth S, Patel A, Foreman M,  The protective role of GLP-1 in neuro-ophthalmology. Explor Drug Sci. 2023;1:221\u2013238."},{"key":"b49","first-page":"654","article-title":"The rate of complications after ventriculoperitoneal shunt surgery","volume":"98","author":"Merkler AE","year":"2017","unstructured":"Merkler AE, Ch\u2019ang J, Parker WE, Murthy SB, Kamel H. The rate of complications after ventriculoperitoneal shunt surgery. World Neurosurg.2017;98:654\u2013658."},{"key":"b50","series-title":"Surg Neurol Int","first-page":"269","article-title":"Ventriculoperitoneal shunt complications in an adult population: a comparison of various shunt designs to prevent overdrainage","volume":"11","author":"Desai VR","year":"2020","unstructured":"Desai VR, Sadrameli SS, Jenson AV,  Ventriculoperitoneal shunt complications in an adult population: a comparison of various shunt designs to prevent overdrainage. Surg Neurol Int. 2020;11:269."},{"issue":"7","key":"b51","series-title":"Neurology","first-page":"e921","article-title":"Mortality among patients with idiopathic intracranial hypertension enrolled in the IH Registry","volume":"95","author":"Hermes SM","year":"2020","unstructured":"Hermes SM, Miller NR, Waslo CS, Benes SC, Tanne E. Mortality among patients with idiopathic intracranial hypertension enrolled in the IH Registry. Neurology. 2020;95(7):e921\u2013e929."},{"issue":"1","key":"b1","series-title":"The International Classification of Headache Disorders, 3rd edition. Cephalalgia","first-page":"1","article-title":"Headache Classification Committee of the International Headache Society (IHS)","volume":"38","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211."},{"key":"b2","series-title":"J Clin Neurosci","first-page":"172","article-title":"Idiopathic intracranial hypertension: pathophysiology, diagnosis and management","volume":"95","author":"Wang MTM","year":"2022","unstructured":"Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci. 2022;95:172\u2013179."},{"issue":"4","key":"b3","series-title":"J Neuroophthalmol","first-page":"258","article-title":"Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension","volume":"27","author":"Warner JEA","year":"2007","unstructured":"Warner JEA, Larson AJ, Bhosale P,  Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol. 2007;27(4):258\u2013262."},{"issue":"11","key":"b4","series-title":"Neurology","first-page":"1893","article-title":"Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension","volume":"64","author":"Tabassi A","year":"2005","unstructured":"Tabassi A, Salmasi AH, Jalali M. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension. Neurology. 2005;64(11):1893\u20131896."},{"issue":"4","key":"b5","series-title":"J Neuroophthalmol","first-page":"253","article-title":"Retinol and retinol-binding protein in cerebrospinal fluid: can vitamin A take the \"idiopathic\" out of idiopathic intracranial hypertension?","volume":"27","author":"Libien J","year":"2007","unstructured":"Libien J, Blaner WS. Retinol and retinol-binding protein in cerebrospinal fluid: can vitamin A take the \"idiopathic\" out of idiopathic intracranial hypertension?. J Neuroophthalmol. 2007;27(4):253\u2013257."},{"issue":"9","key":"b6","series-title":"Dig Dis Sci","first-page":"1847","article-title":"Adipose tissue: the new endocrine organ? A review article","volume":"54","author":"Wozniak SE","year":"2009","unstructured":"Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54(9):1847\u20131856."},{"issue":"4","key":"b7","series-title":"Am J Ophthalmol","first-page":"437","article-title":"Anemia and papilledema","volume":"135","author":"Biousse V","year":"2003","unstructured":"Biousse V, Rucker JC, Vignal C, Crassard I, Katz BJ, Newman NJ. Anemia and papilledema. Am J Ophthalmol. 2003;135(4):437\u2013446."},{"issue":"5","key":"b8","series-title":"Letter. J Intern Med","first-page":"496","article-title":"Inflammatory and haemostatic markers in idiopathic intracranial hypertension","volume":"270","author":"Hannerz J","year":"2011","unstructured":"Hannerz J, Antovic JP, Blomb\u00e4ck M, Edman G, Khademi M, Piehl F. Inflammatory and haemostatic markers in idiopathic intracranial hypertension. Letter. J Intern Med. 2011;270(5):496\u2013499."},{"issue":"4","key":"b9","series-title":"Blood Coagul Fibrinolysis","first-page":"328","article-title":"Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis","volume":"21","author":"Kesler A","year":"2010","unstructured":"Kesler A, Kliper E, Assayag EB,  Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis. Blood Coagul Fibrinolysis. 2010;21(4):328\u2013333."},{"issue":"4","key":"b10","series-title":"Horm Res Paediatr","first-page":"217","article-title":"Idiopathic intracranial hypertension and obesity","volume":"81","author":"Andrews LE","year":"2014","unstructured":"Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr. 2014;81(4):217\u2013225."},{"issue":"5","key":"b11","series-title":"Ophthalmology","first-page":"697","article-title":"Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity","volume":"124","author":"Kilgore KP","year":"2017","unstructured":"Kilgore KP, Lee MS, Leavitt JA,  Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology. 2017;124(5):697\u2013700."},{"issue":"1","key":"b12","series-title":"Int J Obes Relat Metab Disord","first-page":"54","article-title":"The relationship between obesity and idiopathic intracranial hypertension","volume":"23","author":"Rowe FJ","year":"1999","unstructured":"Rowe FJ, Sarkies NJ. The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord. 1999;23(1):54\u201359."},{"issue":"8","key":"b13","series-title":"Cochrane Database Syst Rev","first-page":"CD003434","article-title":"Interventions for idiopathic intracranial hypertension","volume":"2015","author":"Piper RJ","year":"2015","unstructured":"Piper RJ, Kalyvas AV, Young AM, Hughes MA, Jamjoom AA, Fouyas IP. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015;2015(8):CD003434."},{"issue":"3","key":"b14","series-title":"Neurology","first-page":"e208036","article-title":"Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity","volume":"102","author":"Shaia JK","year":"2024","unstructured":"Shaia JK, Sharma N, Kumar M,  Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity. Neurology. 2024;102(3):e208036."},{"issue":"12","key":"b15","series-title":"Ophthalmology","first-page":"2313","article-title":"The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)","volume":"105","author":"Johnson LN","year":"1998","unstructured":"Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105(12):2313\u20132317."},{"issue":"2","key":"b16","series-title":"J Neuroophthalmol","first-page":"197","article-title":"Obesity and weight loss in idiopathic intracranial hypertension: a narrative review","volume":"37","author":"Subramaniam S","year":"2017","unstructured":"Subramaniam S, Fletcher WA. Obesity and weight loss in idiopathic intracranial hypertension: a narrative review. J Neuroophthalmol. 2017;37(2):197\u2013205."},{"issue":"4","key":"b17","series-title":"J Neuroophthalmol","first-page":"522","article-title":"Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention","volume":"38","author":"Hornby C","year":"2018","unstructured":"Hornby C, Mollan SP, Botfield H, O'Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol. 2018;38(4):522\u2013530."},{"issue":"10","key":"b18","series-title":"Expert Opin Pharmacother","first-page":"1305","article-title":"An update on pharmacotherapeutic strategies for obesity","volume":"22","author":"Tchang BG","year":"2021","unstructured":"Tchang BG, Tarazi MS, Aras M, Shukla AP. An update on pharmacotherapeutic strategies for obesity. Expert Opin Pharmacother. 2021;22(10):1305\u20131318."},{"issue":"13","key":"b19","series-title":"Int J Mol Sci","first-page":"10449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu MS","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023;24(13):10449."},{"issue":"8","key":"b20","series-title":"Postgrad Med","first-page":"818","article-title":"User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818\u2013826."},{"key":"b21","series-title":"Obes Med","first-page":"100456","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","author":"Vosoughi K","year":"2022","unstructured":"Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis. Obes Med. 2022;35:100456."},{"issue":"6","key":"b22","series-title":"Adv Ther","first-page":"2452","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle M","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M, Jane\u017e A. Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther. 2022;39(6):2452\u20132467."},{"issue":"6","key":"b23","series-title":"Curr Pain Headache Rep","first-page":"453","article-title":"Idiopathic intracranial hypertension after abrupt cessation of medication: a case report of abrupt glucagon-like peptide-1 (GLP-1) receptor agonist cessation and review of the literature","volume":"28","author":"Heckel B","year":"2024","unstructured":"Heckel B. Idiopathic intracranial hypertension after abrupt cessation of medication: a case report of abrupt glucagon-like peptide-1 (GLP-1) receptor agonist cessation and review of the literature. Curr Pain Headache Rep. 2024;28(6):453\u2013456."},{"issue":"1","key":"b24","series-title":"J Headache Pain","first-page":"89","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"Krajnc N","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S,  Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023;24(1):89."},{"issue":"5","key":"b25","series-title":"Brain","first-page":"1821","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell JL","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK,  The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821\u20131830."},{"issue":"1","key":"b26","series-title":"J Neuroophthalmol","first-page":"6","article-title":"Predictive value of international classification of diseases codes for idiopathic intracranial hypertension in a university health system","volume":"42","author":"Khushzad F","year":"2022","unstructured":"Khushzad F, Kumar R, Muminovic I, Moss HE. Predictive value of international classification of diseases codes for idiopathic intracranial hypertension in a university health system. J Neuroophthalmol. 2022;42(1):6\u201310."},{"issue":"1","key":"b27","series-title":"J Am","first-page":"133","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe JH","year":"2024","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (Wash DC). 2024;64(1):133-138."},{"issue":"11","key":"b28","series-title":"N Engl J Med","first-page":"961","article-title":"Medicare Part D coverage of antiobesity medications\u2014challenges and uncertainty ahead","volume":"388","author":"Baig K","year":"2023","unstructured":"Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare Part D coverage of antiobesity medications\u2014challenges and uncertainty ahead. N Engl J Med. 2023;388(11):961\u2013963."},{"issue":"6","key":"b29","series-title":"Br J Dermatol","first-page":"921","article-title":"Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study","volume":"190","author":"Thang CJ","year":"2024","unstructured":"Thang CJ, Garate D, O\u2019Leary S, Golovko G, Wilkerson MG, Barbieri JS. Evaluation of the association between tetracycline-class antibiotic use in patients with acne and idiopathic intracranial hypertension risk: a population-level cohort study. Br J Dermatol. 2024;190(6):921\u2013923."},{"issue":"1","key":"b30","series-title":"Int Ophthalmol Clin","first-page":"1","article-title":"Epidemiology and risk factors for idiopathic intracranial hypertension","volume":"54","author":"Chen J","year":"2014","unstructured":"Chen J, Wall M. Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin. 2014;54(1):1\u201311."},{"issue":"2","key":"b31","series-title":"J Am Acad Dermatol","first-page":"456","article-title":"Association between cycline antibiotic and development of pseudotumor cerebri syndrome","volume":"81","author":"Eldweik L","year":"2019","unstructured":"Eldweik L, McClelland C, Stein JD, Blachley TS, Lee MS. Association between cycline antibiotic and development of pseudotumor cerebri syndrome. J Am Acad Dermatol. 2019;81(2):456\u2013462."},{"issue":"1-2","key":"b32","series-title":"J Pain","first-page":"59","article-title":"ICD-10 codes for the study of chronic overlapping pain conditions in administrative databases","volume":"21","author":"Schrepf A","year":"2020","unstructured":"Schrepf A, Phan V, Clemens JQ, Maixner W, Hanauer D, Williams DA. ICD-10 codes for the study of chronic overlapping pain conditions in administrative databases. J Pain. 2020;21(1-2):59\u201370."},{"issue":"8","key":"b33","series-title":"JAMA Dermatol","first-page":"895","article-title":"Calcitonin gene-related peptide inhibition and development of acne and rosacea","volume":"160","author":"Thang CJ","year":"2024","unstructured":"Thang CJ, Lai J, Garate D,  Calcitonin gene-related peptide inhibition and development of acne and rosacea. JAMA Dermatol. 2024;160(8):895\u2013898."},{"issue":"8","key":"b34","series-title":"Headache","first-page":"1195","article-title":"Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial","volume":"57","author":"Friedman DI","year":"2017","unstructured":"Friedman DI, Quiros PA, Subramanian PS,  Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache. 2017;57(8):1195\u20131205."},{"issue":"7","key":"b35","series-title":"PLoS One","first-page":"e0236828","article-title":"Idiopathic intracranial hypertension in patients with anemia: a retrospective observational study","volume":"15","author":"Ma Z","year":"2020","unstructured":"Ma Z, Jiang H, Meng C, Cui S, Peng J, Wang J. Idiopathic intracranial hypertension in patients with anemia: a retrospective observational study. PLoS One. 2020;15(7):e0236828."},{"issue":"10","key":"b36","series-title":"JAMA Dermatol","first-page":"1135","article-title":"Temporal trends in the use of systemic medications for acne from 2017 to 2020","volume":"159","author":"Barbieri JS","year":"2023","unstructured":"Barbieri JS. Temporal trends in the use of systemic medications for acne from 2017 to 2020. JAMA Dermatol. 2023;159(10):1135\u20131136."},{"issue":"2","key":"b37","series-title":"Am J Clin Dermatol","first-page":"163","article-title":"Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes","volume":"21","author":"Tan MG","year":"2020","unstructured":"Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. Am J Clin Dermatol. 2020;21(2):163\u2013172."},{"issue":"4","key":"b38","series-title":"Acta Med Port","first-page":"280","article-title":"Kaplan-Meier survival analysis: practical insights for clinicians","volume":"37","author":"Gomes AP","year":"2024","unstructured":"Gomes AP, Costa B, Marques R, Nunes V, Coelho C. Kaplan-Meier survival analysis: practical insights for clinicians. Acta Med Port. 2024;37(4):280\u2013285."},{"key":"b39","series-title":"Exp Diabetes Res","first-page":"672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami M","year":"2012","unstructured":"Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658."},{"issue":"7","key":"b40","series-title":"Eye (Lond)","first-page":"1374","article-title":"Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension","volume":"38","author":"Grech O","year":"2024","unstructured":"Grech O, Mitchell JL, Lyons HS,  Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension. Eye (Lond). 2024;38(7):1374-1379."},{"issue":"1","key":"b41","series-title":"Cerebrospinal Fluid Res","first-page":"10","article-title":"Multiplicity of cerebrospinal fluid functions: new challenges in health and disease","volume":"5","author":"Johanson CE","year":"2008","unstructured":"Johanson CE, Duncan JA III, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008;5(1):10."},{"issue":"404","key":"b42","series-title":"Sci Transl Med","first-page":"eaan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield HF","year":"2017","unstructured":"Botfield HF, Uldall MS, Westgate CSJ,  A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404):eaan0972."},{"issue":"1","key":"b43","series-title":"Nat Commun","first-page":"467","article-title":"Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics","volume":"11","author":"Ast J","year":"2020","unstructured":"Ast J, Arvaniti A, Fine NHF,  Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat Commun. 2020;11(1):467."},{"issue":"1","key":"b44","series-title":"J Endocrinol","first-page":"59","article-title":"A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules","volume":"201","author":"Liu H","year":"2009","unstructured":"Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59\u201366."},{"issue":"17","key":"b45","series-title":"J Neurosci","first-page":"6587","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean PL","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31(17):6587\u20136594."},{"issue":"16","key":"b46","series-title":"JAMA","first-page":"1641","article-title":"Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial","volume":"311","author":"Wall M","year":"2014","unstructured":"Wall M, McDermott MP, Kieburtz KD,  Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641\u20131651."},{"issue":"1","key":"b47","series-title":"BMJ Open Respir Res","first-page":"e000557","article-title":"Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"Schmickl CN","year":"2020","unstructured":"Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. BMJ Open Respir Res. 2020;7(1):e000557."},{"key":"b48","series-title":"Explor Drug Sci","first-page":"221","article-title":"The protective role of GLP-1 in neuro-ophthalmology","volume":"1","author":"Sheth S","year":"2023","unstructured":"Sheth S, Patel A, Foreman M,  The protective role of GLP-1 in neuro-ophthalmology. Explor Drug Sci. 2023;1:221\u2013238."},{"key":"b49","first-page":"654","article-title":"The rate of complications after ventriculoperitoneal shunt surgery","volume":"98","author":"Merkler AE","year":"2017","unstructured":"Merkler AE, Ch\u2019ang J, Parker WE, Murthy SB, Kamel H. The rate of complications after ventriculoperitoneal shunt surgery. World Neurosurg.2017;98:654\u2013658."},{"key":"b50","series-title":"Surg Neurol Int","first-page":"269","article-title":"Ventriculoperitoneal shunt complications in an adult population: a comparison of various shunt designs to prevent overdrainage","volume":"11","author":"Desai VR","year":"2020","unstructured":"Desai VR, Sadrameli SS, Jenson AV,  Ventriculoperitoneal shunt complications in an adult population: a comparison of various shunt designs to prevent overdrainage. Surg Neurol Int. 2020;11:269."},{"issue":"7","key":"b51","series-title":"Neurology","first-page":"e921","article-title":"Mortality among patients with idiopathic intracranial hypertension enrolled in the IH Registry","volume":"95","author":"Hermes SM","year":"2020","unstructured":"Hermes SM, Miller NR, Waslo CS, Benes SC, Tanne E. Mortality among patients with idiopathic intracranial hypertension enrolled in the IH Registry. Neurology. 2020;95(7):e921\u2013e929."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/143\/4\/article-p1037.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/143\/4\/article-p1037.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/143\/4\/article-p1037.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:30:43Z","timestamp":1772721043000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/143\/4\/article-p1037.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":102,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2025.1.jns242357","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}